Revvity Inc (RVTY) PT Raised to $175 at TD Cowen

Tue, 13 Oct 2026 09:30:58 -0400

TD Cowen analyst Dan Brennan raised the price target on Revvity Inc (NYSE: RVTY) to $175.00 (from $130.00) while maintaining a rating.

Revvity to Present at Upcoming Investor Conferences

Tue, 13 Oct 2026 08:00:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

2026 Jefferies Global Healthcare Conference
Tuesday, November 17, 2026
8:00 a.m. GMT – Prahlad Singh, president and chief executive officer

9th Annual Evercore Healthcare Conference
Wednesday, December 2, 2026
9:10 a.m. ET – Prahlad Singh

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the

Revvity to Present at Upcoming Investor Conferences

Tue, 13 Oct 2026 08:00:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

2026 Jefferies Global Healthcare Conference
Tuesday, November 17, 2026
8:00 a.m. GMT – Prahlad Singh, president and chief executive officer

9th Annual Evercore Healthcare Conference
Wednesday, December 2, 2026
9:10 a.m. ET – Prahlad Singh

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the

Revvity Inc (RVTY) PT Raised to $164 at Baird

Thu, 08 Oct 2026 07:23:44 -0400

Baird analyst Catherine Ramsey Schulte raised the price target on Revvity Inc (NYSE: RVTY) to $164.00 (from $144.00) while maintaining a Outperform rating.

Form SCHEDULE 13G/A REVVITY, INC. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Wed, 07 Oct 2026 14:57:00 -0400

si-local-file:///var/storage/secattach/20261007/27160825.html

Revvity Inc (RVTY) PT Raised to $160 at Barclays

Wed, 07 Oct 2026 03:51:59 -0400

Barclays analyst Luke Sergott raised the price target on Revvity Inc (NYSE: RVTY) to $160.00 (from $115.00) while maintaining a Equalweight rating.

Revvity to Host Investor Day

Tue, 06 Oct 2026 08:00:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.

Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.

To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations website following the event.

About Revvity

At Revvity, “impossible”

Revvity to Host Investor Day

Tue, 06 Oct 2026 08:00:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.

Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.

To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations website following the event.

About Revvity

At Revvity, “impossible”

William Blair Starts Revvity Inc (RVTY) at Outperform

Mon, 05 Oct 2026 16:18:03 -0400

William Blair analyst Matt Larew initiates coverage on Revvity Inc (NYSE: RVTY) with a Outperform rating.

The analyst comments "Life sciences inflecting higher, starting multi-quarter run of upward estimate revisions. Our base case 2026 enterprise organic growth target of 4.8% sits at the high end of 4%–5% guidance, and we think consensus across our forecast period will ultimately prove conservative. As Revvity’s two life sciences end-markets, pharma/biotech and academic and government (A&G), recover in tandem alongside an AI tailwind, we see estimates migrating toward a bull case 2028 EPS of $7.23 versus consensus $6.48, a setup we see supporting multiple quarters

William Blair Starts Revvity Inc (RVTY) at Outperform

Mon, 05 Oct 2026 16:18:03 -0400

William Blair analyst Matt Larew initiates coverage on Revvity Inc (NYSE: RVTY) with a Outperform rating.

William Blair Starts Revvity Inc (RVTY) at Outperform

Mon, 05 Oct 2026 16:18:03 -0400

William Blair analyst Matt Larew initiates coverage on Revvity Inc (NYSE: RVTY) with a Outperform rating.

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400